Brief: Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
23/04/2025 12:45
April 23 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: TIZIANA LIFE SCIENCES ANNOUNCES UNIVERSITY OF MASSACHUSETTS COMMENCES DOSING INTRANASAL FORALUMAB IN PHASE 2 MULTIPLE SCLEROSIS TRIAL Source text: ID:nGNX5qmmkT Further company coverage: TLSA.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study